June 9, 2009
by Oral Health
“We started in April supporting 3 clinics running Oral Cancer programs by providing complementary OralAdvance(TM) tests to assess suspicious lesions viewed by dentists. These events were so well attended and supported by the dental community that we agreed to extend our commitment into May and June. In total, by June 19, we will have supported and participated in 6 initiatives in BC and Alberta. These programs are highly valued both to educate communities about cancer and cancer control, and to stimulate proactive oral cancer examinations,” said Dr. Alexei Doudkine, Director of Business Development.
The community-based programs provided interested residents in Richmond (BC), Victoria (BC), Vancouver (BC), and Red Deer (AB) with complimentary oral cancer screenings using VELscope(TM), an oral tissue visualization device. Any areas that looked suspicious for pre-cancer were assessed using OralAdvance(TM), an easy to use, highly informative test that will determine whether cells from the suspicious area have abnormal DNA content as a result of large-scale changes indicative or pre-cancer and cancer. If early cancer is indicated, treatment is straight-forward and patient outcomes are favourable with 5 year survival rates reaching 80-90%.
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance(TM), with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions before biopsy. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.
About PMI Labs
Perceptronix Medical Inc. Laboratories (Vancouver, Canada) provide anatomic pathology and cancer diagnostics services to medical and dental practices in support of earlier diagnoses for better patient outcomes. PMI Labs offers anatomic pathology services with specialized expertise in oncologic pathology, cytopathology, oral pathology, and pathology consultation.
The company uniquely specializes in early cancer detection using quantitative cytology, including tests for oral cancer (OralAdvance(TM)) and lung cancer (LungSign(TM)). Quantitative cytology provides physicians with a distinctive cytopathology assessment based on an objective, computer-based measurement of large-scale DNA abnormality that can indicate precancerous or cancerous changes.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
read more >>